Combining pelvic floor exercises with behavioral therapy could be more effective than current medical treatments at helping men with frequent urges to urinate, new research in men has found. The ...

Source: Getty Images New study results reinforce OAB guidelines recommending behavioral therapy as first-line treatment. Using behavioral therapy first before drugs more effectively reduces voiding ...

The medication vibegron led to improvements in symptoms of overactive bladder and overall quality of life in men undergoing treatment for benign prostatic hyperplasia, according to findings from a ...

A study of NHANES 2005-2020 data found that the prevalence of overactive bladder among men in the US increased significantly from 11.7% in 2009-2014 to 14.5% in 2015-2020. Overactive bladder (OAB) ...

"My bladder is ruining my life," Mr. X said as he sat down on the exam table, already nervous about his first time seeing a urologist. He had considered skipping his appointment, but he simply can't ...

Please provide your email address to receive an email when new articles are posted on . The proportion of men with overactive bladder increased significantly from 2015 to 2020. Results showed ...

Chinese investigators evaluated 15 years' worth of data from more than 18,000 adult men in the U.S. to better characterize OAB and its risk factors. The overall presence of OAB increased significantly ...

THURSDAY, Jan. 2, 2025 (HealthDay News) -- Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) symptoms receiving pharmacologic therapy ...

Bladder issues rarely announce themselves with drama. They begin quietly, a little urgency, a weaker stream, discomfort that shows up at inconvenient times, until they start shaping daily routines.

“How about instead of going out to the movies tonight, we stream one at home instead?” Joanna Wen suggested, trying not to disappoint her family by canceling plans completely…once again. The ...

Credit: Shutterstock. Vibegron is an oral, small molecule beta-3 adrenergic receptor agonist. A phase 3 study evaluating the efficacy and safety of vibegron in men with overactive bladder (OAB) ...